Table 1

Pooled DISCOVER-1 and DISCOVER-2 baseline demographics, disease characteristics and concomitant PsA treatment

GUS Q4WGUS Q8WPBOAll patients
Randomised and treated patients (N)3733753721120
 Male (%)56524852
 Age (years)46464747
 BMI (kg/m2)29292929
 PsA duration (years)6666
 SJC (0–66)11.411.411.511.4
 TJC (0–68)20.819.921.020.6
 CRP (mg/dL)
 csDMARD use at baseline (%)68686868
 MTX use at baseline (%)58566158
 % BSA with psoriasis (0%–100%)1716*15†16‡
 PASI score (0–72)1099†10¶
 FACIT-F (0–52)§312930†30¶
  • Data are mean values unless stated otherwise.

  • *N=372.

  • †N=371.

  • ‡N=1116.

  • §Higher scores indicate less fatigue.

  • ¶N=1119.

  • BMI, body mass index; BSA, body surface area; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; GUS, guselkumab; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PBO, placebo; PsA, psoriatic arthritis; Q4W/Q8W, every 4 weeks/every 8 weeks; SJC, swollen joint count; TJC, tender joint count.